Brief: Lung Cancer Patient In Lantern Pharma’s Harmonic Trial Shows Durable Complete Response In Target Cancer Lesions With Survival Continuing For Nearly Two Years
16/06/2025 13:33
June 16 (Reuters) - Lantern Pharma Inc LTRN.O: LUNG CANCER PATIENT IN LANTERN PHARMA’S HARMONIC TRIAL SHOWS DURABLE COMPLETE RESPONSE IN TARGET CANCER LESIONS WITH SURVIVAL CONTINUING FOR NEARLY TWO YEARS LANTERN PHARMA INC - NO SIGNIFICANT ADVERSE DRUG REACTIONS OVER 21 CYCLES OF TREATMENT LANTERN PHARMA: ANTICIPATES ADDITIONAL DATA UPDATE FROM RANDOMIZED EXPANSION PHASE IN H2 2025 Source text: ID:nBwcclSta Further company coverage: LTRN.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lantern Pharma
See all newsBrief: Lantern Pharma Reports HARMONIC Data Showing LP-300 Progression-Free Survival Benefit Deepens With Treatment Duration In EGFR Exon 21 L858R Lung Cancer
Brief: Lantern Pharma Announces Successful Outcome Of FDA Type C Meeting Request For Harmonic Phase 2 Trial of LP-300 In Never-Smokers With NSCLC
Lantern Pharma Q1 net loss narrows on R&D cost cuts
Brief: Lantern Pharma Inc. Announces Up To $9.25 Million Registered Direct Offering With Existing Holders And A Single Institutional Investor
Brief: Lantern Pharma Inc - Schedules Type C FDA Meeting For Harmonic Protocol Amendments